Skip to main content

Adaptimmune Therapeutics plc - American Depositary Shares (NQ:ADAP)

0.2500 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 13, 2025 Add to My Watchlist

Price and Volume

Detailed Quote
Volume 95,412
Open 0.2500
Bid (Size) 0.2200 (10)
Ask (Size) 0.2349 (3)
Prev. Close 0.2500
Today's Range 0.2500 - 0.2500
52wk Range 0.1951 - 1.480
Shares Outstanding 1,535,653,620
Dividend Yield N/A

Performance

YTD
-59.9%
-59.9%
1 Month
+6.9%
+6.9%
3 Month
-56.6%
-56.6%
6 Month
-68.5%
-68.5%
1 Year
-78.6%
-78.6%

More News

Read More

Frequently Asked Questions

Is Adaptimmune Therapeutics plc - American Depositary Shares publicly traded?
Yes, Adaptimmune Therapeutics plc - American Depositary Shares is publicly traded.
What exchange does Adaptimmune Therapeutics plc - American Depositary Shares trade on?
Adaptimmune Therapeutics plc - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Adaptimmune Therapeutics plc - American Depositary Shares?
The ticker symbol for Adaptimmune Therapeutics plc - American Depositary Shares is ADAP on the Nasdaq Stock Market
What is the current price of Adaptimmune Therapeutics plc - American Depositary Shares?
The current price of Adaptimmune Therapeutics plc - American Depositary Shares is 0.2500
When was Adaptimmune Therapeutics plc - American Depositary Shares last traded?
The last trade of Adaptimmune Therapeutics plc - American Depositary Shares was at 05/13/25 04:00 PM ET
What is the market capitalization of Adaptimmune Therapeutics plc - American Depositary Shares?
The market capitalization of Adaptimmune Therapeutics plc - American Depositary Shares is 383.91M
How many shares of Adaptimmune Therapeutics plc - American Depositary Shares are outstanding?
Adaptimmune Therapeutics plc - American Depositary Shares has 384M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.